San Diego biotech starts clinical study of self-replicating RNA vaccine for rabies

Ryan Cross

Senior Science Correspondent

Replicate Bioscience, a biotech startup designing next-generation mRNA vaccines to trigger stronger and longer-lasting immune responses, has begun its first clinical study, the San Diego …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

San Diego biotech starts clinical study of self-replicating RNA vaccine for rabies

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

San Diego biotech starts clin­i­cal study of self-repli­cat­ing RNA vac­cine for ra­bies

Senior Science Correspondent

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

San Diego biotech starts clinical study of self-replicating RNA vaccine for rabies